ArticleBlood advances2025
Safety and efficacy of glofitamab for relapsed/refractory large B-cell lymphoma in a multinational real-world study.
Article in Blood advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Outcomes of real-world complete responders after fixed duration glofitamab in relapsed/refractory large B-cell lymphoma.Haematologica · 2026Article
- Hypersensitivity Reactions to Biologics: Advances in Diagnosis and Management.Current allergy and asthma reports · 2026Review
- Real-World Efficacy and Safety of Glofitamab-Based Salvage Therapy in Chinese Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas.American journal of hematology · 2026Observational
- Feasibility and safety of rapid glofitamab ramp-up.Leukemia · 2026Article
- Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.Blood advances · 2026Article
- Prognostic role of FDG-PET in patients with relapsed/refractory large B-cell lymphoma treated with CD3-CD20 directed bispecific antibodies: a multicentric analysis.European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Unraveling the immune microenvironment in primary CNS lymphoma.Biomarker research · 2026Review
- TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.Annals of hematology · 2026Article
- [Glofitamab for relapsed/refractory B-cell lymphoma: analysis of efficacy and influencing factors].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Article
- Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma.Blood advances · 2026Article
- Clinical Impact of a LAG3 Single-Nucleotide Polymorphism in Relapsed, Refractory DLBCL Patients Treated with Glofitamab.Cancers · 2026Article
- Prognostic value of inflammation-based scores in patients with R/R LBCL treated with CD3×CD20 bispecific T-cell engagers.Blood advances · 2026Article
- CD3xCD20 bispecific antibodies in transformed Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.HemaSphere · 2026Article
- Case Report: Long-term survival of refractory high-grade B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements through glofitamab monotherapy consolidated by ASCT.Frontiers in immunology · 2026Article
- Estimation of benefit to bispecific antibodies in US patients with lymphoma and multiple myeloma.Blood advances · 2025Article
- Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma.Blood advances · 2025Article
- Immunotherapy in chronic lymphocytic leukemia: advances and challenges.Experimental hematology & oncology · 2025Review
- Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2025Review
- Case report of two patients with refractory HIV-related B-cell lymphoma treated with the monoclonal antibody glofitamab for secondary central nervous system involvement.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractGlofitamab, a bispecific antibody targeting CD20 and CD3, is approved for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL) after at least 2 prior treatment lines, but real-world data are scarce. In this retrospective, multicenter, multinational study, we evaluated the outcomes of 70 patients with r/r DLBCL treated with glofitamab as part of the compassionate use patient program in Germany, Austria, and Switzerland. The median number of prior treatment lines was 4, with 71% of patients refractory to their last treatment. Cytokine release syndrome was observed in 40% of patients (grade 3-4 in 2%), immune effector cell-associated neurotoxicity syndrome in 10% (grade 3 in 1%), and infections in 31% (grade 5 in 3%). The overall response rate was 46%, with 27% achieving complete responses (CR) and 19% partial responses. The median progression-free survival (PFS) was 3.6 months, whereas the median overall survival was 5.7 months. Notably, 13 patients (19%) were in CR 6 months after initiating glofitamab and exhibited durable responses. Elevated lactate dehydrogenase is the most robust predictor of inferior outcome. Patients pretreated with bendamustine within 6 months prior to glofitamab initiation exhibited significantly reduced PFS, suggesting that bendamustine may impair T-cell fitness and hence glofitamab efficacy. In summary, glofitamab demonstrates promising efficacy and a manageable safety profile in heavily pretreated patients with r/r DLBCL in a real-world scenario and the optimal sequence of treatments should use T-cell-depleting agents before glofitamab with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.